ACS Chem Biol:从卫矛属中发现治疗帕金森氏症新化合物

2014-03-26 中国科学报 中国科学报

据报道,日前从上海交通大学获悉,该校系统生物医学研究院吴方课题组和药学院张卫东课题组通过开展生物学与化学多学科交叉与合作,从我国西双版纳特有植物中发现了一种可治疗帕金森氏症的天然产物。  帕金森氏症是一种常见的神经退行性疾病,在全球影响着600多万患者。而多巴脱羧酶是治疗帕金森氏症的药物靶点蛋白。 吴方和张卫东课题组等通过构建新型高通量药物筛选模型,从西双版纳特有的卫矛属植物

据报道,日前从上海交通大学获悉,该校系统生物医学研究院吴方课题组和药学院张卫东课题组通过开展生物学与化学多学科交叉与合作,从我国西双版纳特有植物中发现了一种可治疗帕金森氏症的天然产物。 

帕金森氏症是一种常见的神经退行性疾病,在全球影响着600多万患者。而多巴脱羧酶是治疗帕金森氏症的药物靶点蛋白。

吴方和张卫东课题组等通过构建新型高通量药物筛选模型,从西双版纳特有的卫矛属植物Euonymus glabraRoxb.中发现得到了一种结构全新的天然产物。研究发现,该产物可以在体外和细胞水平抑制多巴脱羧酶的活力。 

业内专家认为,该项研究发现的新型化合物具有独特的多巴胺二倍体结构,为多巴胺相关疾病的治疗和预防研究提供了新的候选药物和分子探针工具。

原始出处:

Ren J, Zhang Y, Jin H, Yu J, Zhou Y, Wu F, Zhang W.Novel Inhibitors of Human DOPA Decarboxylase Extracted from Euonymus glabra Roxb.ACS Chem Biol. 2014 Feb 10.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1917031, encodeId=37f1191e03157, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri May 02 17:37:00 CST 2014, time=2014-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1906284, encodeId=c4971906284f6, content=<a href='/topic/show?id=7795334e220' target=_blank style='color:#2F92EE;'>#化合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33472, encryptionId=7795334e220, topicName=化合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Mon May 26 04:37:00 CST 2014, time=2014-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1766870, encodeId=45ac1e668707a, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Fri Apr 11 17:37:00 CST 2014, time=2014-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279048, encodeId=1de812e9048e7, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Fri Mar 28 00:37:00 CST 2014, time=2014-03-28, status=1, ipAttribution=)]
    2014-05-02 sunylz
  2. [GetPortalCommentsPageByObjectIdResponse(id=1917031, encodeId=37f1191e03157, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri May 02 17:37:00 CST 2014, time=2014-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1906284, encodeId=c4971906284f6, content=<a href='/topic/show?id=7795334e220' target=_blank style='color:#2F92EE;'>#化合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33472, encryptionId=7795334e220, topicName=化合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Mon May 26 04:37:00 CST 2014, time=2014-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1766870, encodeId=45ac1e668707a, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Fri Apr 11 17:37:00 CST 2014, time=2014-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279048, encodeId=1de812e9048e7, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Fri Mar 28 00:37:00 CST 2014, time=2014-03-28, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1917031, encodeId=37f1191e03157, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri May 02 17:37:00 CST 2014, time=2014-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1906284, encodeId=c4971906284f6, content=<a href='/topic/show?id=7795334e220' target=_blank style='color:#2F92EE;'>#化合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33472, encryptionId=7795334e220, topicName=化合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Mon May 26 04:37:00 CST 2014, time=2014-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1766870, encodeId=45ac1e668707a, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Fri Apr 11 17:37:00 CST 2014, time=2014-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279048, encodeId=1de812e9048e7, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Fri Mar 28 00:37:00 CST 2014, time=2014-03-28, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1917031, encodeId=37f1191e03157, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri May 02 17:37:00 CST 2014, time=2014-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1906284, encodeId=c4971906284f6, content=<a href='/topic/show?id=7795334e220' target=_blank style='color:#2F92EE;'>#化合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33472, encryptionId=7795334e220, topicName=化合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Mon May 26 04:37:00 CST 2014, time=2014-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1766870, encodeId=45ac1e668707a, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Fri Apr 11 17:37:00 CST 2014, time=2014-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279048, encodeId=1de812e9048e7, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Fri Mar 28 00:37:00 CST 2014, time=2014-03-28, status=1, ipAttribution=)]
    2014-03-28 yaanren

相关资讯

J Immunol:IL-13受体在帕金森氏病患者多巴胺能神经元损伤中扮演关键作用

    解读是什么原因导致帕金森氏病患者脑细胞变性仍然是一个令人费解的科学挑战。不过,近来斯克里普斯研究所(TSRI)科学家领导的研究小组指出了帕金森氏症小鼠模型中控制脑细胞损伤的一个关键因素。这一发现可能导致新治疗方式来治疗帕金森氏在。研究小组由TSRI神经科学家Bruno Conti领导,相关研究论文发表在2012年11月19日的Journal of Immuno